Skip to main content
Fig. 12 | Journal of Translational Medicine

Fig. 12

From: Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model

Fig. 12

Screening of therapeutic agents for BLCA based on risk models. A For the GDSC database, Spearman correlation analysis was performed on BLCA and estimated IC50 values. With a filtering |R| greater than 0.4 and p-value less than 0.05, 12 candidate compounds were identified. B Sensitivity analysis of key drugs in high- and low-risk groups. C AUC values of CTRP compounds were estimated for each BLCA patient and Spearman analysis was performed on BLCA and AUC values. Dotted line plots visualize the 5 compounds with the highest negative correlation coefficients. D The AUC values estimated by the compounds were significantly lower in the high-risk group of BLCA

Back to article page